EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Flagellins as Vaccine Adjuvants and Cancer Immunotherapy: Recent Advances and Future Prospects

Asma Talukder, Md Mijanur Rahman iD, Md Sifat Rahi, Dean L Pountney, Ming Q Wei

Immunology · 2025-11 · 176 (3) · 277-303

DOI: 10.1111/imm.70001 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunology, online erschienen am 10.06.2025. Verfasst von Asma Talukder und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Medical Sciences, Griffith University, Gold Coast, Queensland, Australia. Hauptthemen laut MEDLINE: Neoplasms, Cancer Vaccines, Immunotherapy, Flagellin. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 161 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Flagellin, an essential structural protein of bacterial flagella, has emerged as a potent modulator of both specific and nonspecific immunity, demonstrating significant potential as a vaccine adjuvant and carrier. By inducing the release of pro‐inflammatory cytokines like IL‐1β, TNF‐α, IL‐6, IL‐8, and IL‐12, flagellin activates the innate immune system, enhancing antigen‐specific adaptive immune responses mediated by tumour‐specific type 1 helper T cells and cytotoxic T cells, thus positioning it as a valuable adjuvant or complementary therapy for various cancers and infectious diseases. This review explores recent strategies, innovations, and clinical applications of flagellin‐based immunotherapies, particularly in the context of infectious diseases and cancers. Flagellin from Salmonella typhimurium has been extensively studied as a vaccine adjuvant for diseases like HIV, influenza, dengue, West Nile virus, poultry cholera, and bursal diseases and shows promise in treating lung metastasis, melanoma, colon, and prostate cancers. It has also proven effective against multidrug‐resistant bacteria, including Pseudomonas aeruginosa and S. typhimurium . Notably, S. typhimurium flagellin‐based vaccines for influenza have progressed to clinical trials. Additionally, flagellins from S. typhi , S. enteritidis , P. aeruginosa , and Escherichia coli are being evaluated as vaccine candidates for plague, malaria, and infections caused by P. aeruginosa and E. coli . In cancer therapy, flagellin‐based treatments, especially when combined with tumour antigens, have exhibited the ability to enhance anti‐tumour immunity and improve patient outcomes. Other flagellin‐based vaccines derived from S. Dublin , S. munchen , and Vibrio vulnificus have been employed in the treatment of prostate, lung, liver, breast, cervical, and colorectal cancers, as well as lymphoma, melanoma, and radiation‐induced mucositis. Mobilan, a recombinant non‐replicating adenovirus vector expressing Salmonella flagellin, is currently in a phase Ib clinical trial for prostate cancer. Overall, bacterial flagellin treatments are generally safe, well‐tolerated, and associated with minimal side effects, making them a promising option for managing infectious diseases and cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsCancer VaccinesImmunotherapyFlagellinAdjuvants, ImmunologicAdjuvants, VaccineHumansAnimalsSalmonella typhimurium

Stichwörter der Autor:innen

adjuvantscancerflagellinimmunotherapyinfectious diseasesvaccine

Substanzen

Cancer VaccinesFlagellinAdjuvants, ImmunologicAdjuvants, Vaccine

Autor:innen und Institutionen

  • School of Pharmacy and Medical Sciences, Griffith University, Gold Coast, Queensland, Australia.

ORCID-Profile: Md Mijanur Rahman

Zitieren

APA

Talukder, A., Rahman, M. M., Rahi, M. S., Pountney, D. L., & Wei, M. Q. (2025). Flagellins as Vaccine Adjuvants and Cancer Immunotherapy: Recent Advances and Future Prospects. Immunology, 176(3), 277-303. https://doi.org/10.1111/imm.70001

Vancouver

Talukder A, Rahman MM, Rahi MS, Pountney DL, Wei MQ. Flagellins as Vaccine Adjuvants and Cancer Immunotherapy: Recent Advances and Future Prospects. Immunology. 2025;176(3):277-303. doi:10.1111/imm.70001

BibTeX
@article{Talukder2025,
  author = {Talukder, Asma and Rahman, Md Mijanur and Rahi, Md Sifat and Pountney, Dean L and Wei, Ming Q},
  title = {Flagellins as Vaccine Adjuvants and Cancer Immunotherapy: Recent Advances and Future Prospects},
  journal = {Immunology},
  year = {2025},
  volume = {176},
  number = {3},
  pages = {277--303},
  doi = {10.1111/imm.70001}
}
Kostenlos starten →